Subscribe

Conference Correspondent

Daratumumab, Bortezomib, Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated Efficacy Analysis of CASTOR
Conference Correspondent, ASH
Conference Correspondent 

By prior treatment exposure, all subgroups in the CASTOR trial benefited from the addition of daratumumab to bortezomib/dexamethasone, including patients refractory to lenalidomide at last treatment.

Read More ›
A Look at Daratumumab
A Look at Daratumumab
By Leslie Lauersdorf, ARNP
Conference Correspondent, ASH
Conference Correspondent 
Leslie Lauersdorf discusses her perceptions regarding daratumumab therapy and identifies how her patients have benefited from this treatment option. Read More ›
Daratumumab: What Patients Want to Know
Daratumumab: What Patients Want to Know
By Leslie Lauersdorf, ARNP
Conference Correspondent, ASH
Conference Correspondent 
Leslie Lauersdorf addresses the different questions her patients ask her when they begin daratumumab therapy. Read More ›
Managing Treatment-Related Toxicities
Managing Treatment-Related Toxicities
By Leslie Lauersdorf, ARNP
Conference Correspondent, ASH
Conference Correspondent 
Leslie Lauersdorf explains why it's so important to understand the patient's baseline to help manage side effects. Read More ›
The Janssen CarePath Program and the Cost of Care
The Janssen CarePath Program and the Cost of Care
By Leslie Lauersdorf, ARNP
Conference Correspondent, ASH
Conference Correspondent 
Leslie Lauersdorf has seen the Janssen CarePath Program help alleviate some of the financial burden of treatment for her patients. Read More ›
Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen
Conference Correspondent, ASH
Conference Correspondent 
Recent data indicate that daratumumab can further decrease minimal residual disease burden when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma. Read More ›
Meta-Analysis to Compare Efficacy of Treatment Regimens for Patients with Relapsed/Refractory Multiple Myeloma
Conference Correspondent, ASH
Conference Correspondent 
Researchers conducted a systematic literature review and subsequent meta-analysis of progression-free survival outcomes to compare 16 different treatment regimens for relapsed/refractory multiple myeloma. Read More ›
Results of an Early Access Treatment Protocol of Daratumumab in US Patients with Relapsed or Refractory Multiple Myeloma
Conference Correspondent, ASH
Conference Correspondent 
An early access study confirms the safety and preservation of health-related quality of life of daratumumab in multiple myeloma. Read More ›
Potentiation of Antimyeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide, or Bortezomib via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP
Conference Correspondent, ASH
Conference Correspondent 
Combinations of targeted agents that include daratumumab offer synergy to alter the tumor microenvironment to promote the efficacy of these combinations in the treatment of multiple myeloma. Read More ›
PREAMBLE: Real-World Efficacy Analyses in Multiple Myeloma Patients with 1 Line of Prior Therapy
Conference Correspondent, ASH
Conference Correspondent 
PREAMBLE is an ongoing multinational observational study being conducted to evaluate real-world outcomes in patients with multiple myeloma. Here, researchers present preliminary efficacy analyses in patients with 1 line of prior therapy. Read More ›

Page 11 of 32


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.